First-in-human clinical trial of human iPSC-derived cardiomyocytes reported by Nature News


HELP Therapeutics sponsored the first-in-human clinical trial of human allogeneic heart muscle cells (known as cardiomyocytes) derived from induced pluripotent stem cells (iPSCs). 

In May 2019, two men in China were the first people in the world to receive cell therapy for heart disease based on “reprogrammed” iPSCs. This was reported by Nature News on May 13, 2020. 

The surgeries were performed by Professor WANG Dongjin at Nanjing Drum Tower Hospital, using cardiomyocytes produced by HELP Therapeutics. 

Founded in 2016, HELP Therapeutics has developed the capability to produce large numbers of iPSC-derived cardiomyocytes pure enough to be used in people, under GMP conditions.


Original links:  

Revealed: two men in China were first to receive pioneering stem-cell treatment for heart disease (